IP Library › Granted Patent US 10,577,351
Granted Patent B2
US 10,577,351 · App. 16/019,982 · Granted Mar 3, 2020

Therapeutic polymeric nanoparticles and methods of making and using same

Inventors: Marianne Bernice Ashford (Macclesfield, GB); James Martin Nolan, III (Cambridge, MA); Eyoung Shin (Cambridge, MA); Young-Ho Song (Cambridge, MA); Greg Troiano (Cambridge, MA); Hong Wang (Cambridge, MA)
Assignee: ASTRAZENECA AB
C07D403/12A61K9/0019A61K9/16A61K9/5123A61K9/5153A61K31/517A61K31/675A61K45/06A61K47/10A61K47/12A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,577,351
App. No.
16/019,982
Granted
Mar 3, 2020
Kind
B2
Abstract

Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.

Claims (10)

1. A method of treating a cancer selected from a haematological cancer and lung cancer comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition comprising therapeutic nanoparticles, wherein said nanoparticles comprise

from about 15 to about 25 weight percent of 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide,

about 7 to about 15 weight percent of pamoic acid, and

a diblock poly(lactic acid)-poly(ethylene glycol) copolymer; wherein the diblock poly(lactic acid)-poly(ethylene glycol) copolymer has a poly(lactic acid) block having a number average molecular weight of about 16 kDa and a poly(ethylene glycol) block having a number average molecular weight of about 5 kDa; wherein the poly(ethylene glycol) block comprises about 10 to 30 weight percent of the therapeutic nanoparticle.

2. The method of claim 1 , wherein the warm-blooded animal is man.

3. The method of claim 1 , wherein the haematological cancer is selected from chronic myelogenous leukemia, chronic myelomonocytic leukemia, Philadelphia chromosome positive acute lymphoblastic leukemia, mantle cell lymphoma, acute myeloid leukemia, diffuse large B cell lymphoma, myeloma, peripheral T-cell lymphoma and myelodysplastic syndrome.

4. The method of claim 3 , wherein the haematological cancer is acute myeloid leukemia.

5. The method of claim 3 , wherein the haematological cancer is diffuse large B cell lymphoma.

6. The method of claim 3 , wherein the haematological cancer is myelodysplastic syndrome.

7. The method of claim 1 , wherein the lung cancer is small cell lung cancer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: BIND THERAPEUTICS INC.
To: ASTRAZENECA AB
Reel/Frame 047331/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: ASHFORD, MARIANNE BERNICE
To: ASTRAZENECA UK LIMITED
Reel/Frame 046357/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: SONG, YOUNG-HO; SHIN, EYOUNG; NOLAN, JAMES MARTIN, III; TROIANO, GREG; WANG, HONG
To: BIND THERAPEUTICS INC,
Reel/Frame 046358/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: ASTRAZENECA UK LIMITED
To: ASTRAZENECA AB
Reel/Frame 046358/0088 →
Continuity (4)
Continuation 14485875 · Sep 15, 2014
Provisional Application 61878227 · Sep 16, 2013
Provisional Application 61939332 · Feb 13, 2014
Related Publication 20190092757A1 · Mar 28, 2019